Navigation Links
Oncogene AEG-1 strongly predicts response to erlotinib treatment in EGFR-mutant lung cancer
Date:2/25/2011

Spanish researchers have identified a gene whose expression level strongly predicts how well certain lung cancer patients will respond to treatment with the drug erlotinib.

Dr Rafael Rosell and colleagues reported their findings at the European Multidisciplinary Conference in Thoracic Oncology (EMCTO), 24-26 February 2011 in Lugano, Switzerland.

The researchers studied 55 patients with non-small cell lung cancer, whose tumors had mutations in the epidermal growth factor receptor (EGFR) gene. All were being treated with the drug erlotinib, which acts on the EGFR molecule.

"Currently we have no predictors for the duration of response to EGFR drugs in non-small cell lung cancer patients with EGFR mutation," Dr Rosell explained. "The median progression-free survival time for these patients ranges from 10 to 14 months, but there is a subgroup of patients with very short response while others have long lasting benefit."

Researchers in the Spanish Lung Cancer Group (SLCG), in cooperation with Pangaea Biotech, USP Dexeus University Institute, Barcelona -- which acts as one of the reference laboratories for the SLCG -- set out to find genes that predicted which patients would have a lasting benefit, and which would not. To do this, they used a technology called NanoString. "NanoString is an integrated digital technology with high levels of precision and sensitivity that detects expression levels of hundreds of genes in a single reaction, making it suitable for clinical use," Dr Rosell explained.

Dr Rosell and colleagues used the technology to examine expression levels of 48 different genes in 43 patients with EGFR-mutant non-small cell lung cancer who were being treated with erlotinib.

They found that AEG (astrocye elevated gene 1, also known as metadherin) was the strongest predictor of progression-free survival in these patients. Progression-free survival was 27 months for those with low AEG-1 expression, compare
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Fox Chase researchers uncover one force behind the MYC oncogene in many cancers
2. Doctors not strongly encouraging HPV vaccine to girls of certain age
3. New model predicts hot spots for mercury in fish
4. Pregnancy hormone predicts postpartum depression
5. Stroma genomic signature predicts resistance to anthracyclin-based chemotherapy in breast cancer
6. Study predicts when invasive species can travel more readily by air
7. Blood test predicts chance of dementia
8. Computer model predicts brain tumor growth and evolution
9. NOAA forecast predicts large dead zone for Gulf of Mexico this summer
10. Gene predicts how brain responds to fatigue, human study shows
11. Blood-flow metabolism mismatch predicts pancreatic tumor aggressiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... The Chinese University of Hong Kong, BGI and other ... to salt tolerance, with implication for improving this important ... online in Nature Communications provides an effective ... , Soybean is an important crop for the world. ... less genetic diversities than their wild counterparts. Among the ...
(Date:7/11/2014)... Salk Institute for Biological Studies, BGI, and other ... and reliability of the existing targeted gene correction ... which could significantly increased gene-correction efficiency in human ... online in Cell Stell Cell provides ... therapy. , The combination of stem cells and ...
(Date:7/11/2014)... animals often develop relationships with other group members to ... wild chacma baboons the strategy for grooming activities shows ... just published in the scientific journal Biology Letters ... baboons is not practiced without ulterior motives. To be ... the individual, while grooming another individual can provide access ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2A new genome editing method brings the possibility of gene therapies closer to reality 2Baboons groom early in the day to get benefits later 2
... Calif.Flies follow horizontal edges to regulate altitude, says a ... (Caltech). This finding contradicts a previous model, which posited ... motion beneath them as they fly. This mechanism ... to track horizontal edges in their environmentis very similar ...
... extinct in Europe 24,000 years ago, but until now the ... mitochondrial DNA sequences from 17 new fossil samples, and compared ... the decline of the cave bear started 50,000 years ago, ... change. "The decline in the genetic diversity of the ...
... is available in Spanish . ... chemist Richard Anderson suggests that a water soluble extract ... risk factors associated with diabetes and heart disease. ... between the Beltsville Human Nutrition Research Center (BHNRC) ...
Cached Biology News:Fruit flies use horizontal landmarks for altitude control, says Caltech research team 2Fruit flies use horizontal landmarks for altitude control, says Caltech research team 3Fruit flies use horizontal landmarks for altitude control, says Caltech research team 4True causes for extinction of cave bear revealed 2Researchers study cinnamon extracts 2
(Date:7/11/2014)... , July 11, 2014 Research ... "International Transfection Technology Market - Global Industry Analysis, Size, ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... introduce nucleic acids (either DNA or RNA) into cells. ... mutation of cancer cells and protein metabolism by affecting ...
(Date:7/11/2014)... 11, 2014 BCC Research ( http://www.bccresearch.com ... POLYMERASE CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , the ... reached nearly $140 billion in 2013. This is estimated ... five-year compound annual growth rate (CAGR) of 28.6%. , ... interesting and exciting possibilities within the broader PCR field. ...
(Date:7/11/2014)... 2014 EPFL and the University of  ... of John P. Donoghue . The American neuroscientist ... . The new Wyss Center for ... Geneva , has named as its director ... P. Donoghue , founder of Brown University,s Institute for ...
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada ... TM (eslicarbazepine acetate) for use as a once-daily ... patients with epilepsy who are not satisfactorily controlled with ... use in patients under 18 years of age. ... neurological disorders and according to Epilepsy Canada, it affects ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4
... Demonstrated at HIMSS 2009BERKELEY HEIGHTS, N.J., April 6 ... ADAT ), a worldwide provider of secure ... announced that it has integrated Authentidate,s Inscrybe(TM) Healthcare ... hospital patient discharges. "Hospitals are looking to automate ...
... Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today ... (Spectrum) in connection with the sale of its 50% ... approximately $16.5 million that closed in March 2009. CTI ... related to this transaction, and the remaining $3.5 million, ...
... VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), ... for the treatment of cardiovascular and metabolic disease, today ... 31, 2009, from the staff of the NASDAQ Stock ... comply with NASDAQ Marketplace Rule 4310(c)(3). NASDAQ Marketplace ...
Cached Biology Technology:Authentidate Teams with Nortel to Enhance Hospital Patient Discharge and Placement Processes 2Authentidate Teams with Nortel to Enhance Hospital Patient Discharge and Placement Processes 3Authentidate Teams with Nortel to Enhance Hospital Patient Discharge and Placement Processes 4CTI Receives the Second Payment of $6.5 million Associated with the Sale of Interest in Zevalin Joint Venture 2CTI Receives the Second Payment of $6.5 million Associated with the Sale of Interest in Zevalin Joint Venture 3VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ 2VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ 3VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ 4
ANTI MYCOBACTERIUM TUBERCULOSIS...
IMAGEQUANT 100 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
ImageQuant 100 UV, 1 EA. Category: ImageQuant CCD Imagers....
The FlowTACS Apoptosis Detection Kit is designed specifically for in situdetection of apoptotic...
Biology Products: